We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials
Esketamine's effectiveness and safety for hard-to-treat depression: a detailed analysis of patient data from controlled trials
AI simplified
Abstract
Re-analysis of data from 1505 patients shows that esketamine combined with an antidepressant reduced depression scores by an average of 2.94 points at 4 weeks compared to placebo.
- Esketamine in combination with an antidepressant is associated with a moderate reduction in depression scores as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS).
- A continuation trial indicates a reduced risk of relapse with esketamine treatment.
- Monotherapy with esketamine appears to show a larger effect on depression scores, though concerns regarding selection bias exist.
- Esketamine is linked to increased sedation, dissociation, and adverse events, although serious adverse events were not found to be more frequent.
- No significant differences in treatment effects were observed based on patient age or level of treatment resistance.
AI simplified
Key numbers
0.38
for Relapse
Efficacy observed in continuation trials for esketamine.
3 points
Mean Difference on
Primary outcome of efficacy in the meta-analysis.
7 times
Increase in Adverse Events
Comparative increase in adverse events reported in trials.